What is IBIO's current stock price?

IBIO (iBio, Inc.) is currently trading at $1.84 with a market cap of $29.1M.

What sector is iBio, Inc. in?

iBio, Inc. (IBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IBIO a good stock to buy?

Analysts have a Buy consensus on IBIO with a price target of $2.80. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IBIO iBio, Inc.

Healthcare

$1.84-2.65%ClosedMarket Cap: $29.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.84

P/S

96.84

EV/EBITDA

0.72

DCF Value

$0.24

FCF Yield

-76.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

-160.0%

Operating Margin

-7985.3%

Net Margin

-9202.0%

ROE

-53.9%

ROA

-32.2%

ROIC

-30.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$0.00	$-7.7M	$—
Q2 null	$0.00	$-9.0M	$—
Q1 null	$100.0K	$-5.7M	$—
Q4 null	$200.0K	$-5.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.80

Target (Median)

$2.80

Target Range

$2.00 - $3.60

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-04-09

Chardan CapitalBuy

2026-02-12

Chardan CapitalBuy

2025-06-25

Trading Activity

Insider Trades

View All

Stoner Elizabethdirector

SellTue May 19

Stoner Elizabethdirector:

SellFri May 15

Banjak Marcofficer: Chief Legal Officer

BuyFri Mar 27

Banjak Marcofficer: Chief Legal Officer

BuyFri Mar 27

Duran Felipeofficer: Chief Financial Officer

BuyMon Mar 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.24

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Peers